CA Patent

CA2536378A1 — Rifamycin analogs and uses thereof

Assigned to Activbiotics Inc · Expires 2005-03-10 · 21y expired

What this patent protects

The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-pos…

USPTO Abstract

The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivated at various positions of the benzene ring, including 3~-hydroxy analogs, 4~-and/or 6~halo and/or alkoxy analogs, and various 5~ substituents that incorporate a cyclic amine moiety.

Drugs covered by this patent

Patent Metadata

Patent number
CA2536378A1
Jurisdiction
CA
Classification
—
Expires
2005-03-10
Drug substance claim
No
Drug product claim
No
Assignee
Activbiotics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.